WHO appreciates UK’s dexamethasone trial results reducing deaths of seriously-ill Coronavirus patients
The World Health Organisation (WHO) on Wednesday expressed its happiness over the initial clinical Coronavirus recovery trial results from a low-dose steroid called Dexamethasone. The study claimed to have successfully cut down the mortality rate in severe patients by one third and those on ventilators by one fifth.
The study was carried out by Oxford University researchers in the United Kingdom. The study said that the medicine had worked well in seriously ill patients only and was not observed in those with milder symptoms.
The agency tweeted, “WHO welcomes the initial clinical trial results from the #UnitedKingdom that show #dexamethasone, a corticosteroid, can be lifesaving for patients who are critically ill with #COVID19.”
WHO Director-General Dr Tedros Adhanom Ghebreyesus said, “This is the first treatment to be shown to reduce mortality in patients with COVID-19 requiring oxygen or ventilator support.”
The Chief added, "WHO will coordinate a meta-analysis to increase our overall understanding of this intervention. WHO clinical guidance will be updated to reflect how and when the drug should be used in COVID-19.”
He also congratulated the university and the UK government for the major life-saving breakthrough that can help reduce the global death count which now stands at 446,182. The global count of Novel Coronavirus cases is 8,265,941 with the United States of America topping the chart with 2,208,400 confirmed cases and 119,132 fatalities. The UK stands on the fifth position with 298,136 cases and 41,969 deaths.
According to the WHO, dexamethasone is a steroid which has been in use since the 1960s to reduce inflammation, including inflammatory disorders and certain cancers.